Stock KHTRF KNIGHT THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Knight Therapeutics Inc. OTC Markets

Equities

KHTRF

CA4990531069

Market Closed - OTC Markets
Other stock markets
 03:11:59 2024-07-12 pm EDT 		5-day change 1st Jan Change
4.18 USD -0.71% Intraday chart for Knight Therapeutics Inc. +1.95% +5.56%
Jul. 11 Knight Therapeutics Announced Normal Course Issuer Bid MT
Jul. 11 Knight Therapeutics Brief: Announcing Normal Course Issuer Bid MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Knight Therapeutics Announced Normal Course Issuer Bid
MT
Knight Therapeutics Brief: Announcing Normal Course Issuer Bid
MT
Knight Therapeutics Inc. announces an Equity Buyback for 5,312,846 shares, representing 5.24% of its issued share capital.
CI
Knight Therapeutics Inc. authorizes a Buyback Plan.
CI
Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1
MT
Knight Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Knight Therapeutics Brief: Q1 Net loss was $4.546 Million; Revenues were $86.604 Million
MT
Knight Therapeutics Brief: Entering into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM In Canada and Latin America
MT
Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024
CI
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for Jornay Pm® for Canada and Latin America
CI
Knight Therapeutics Reports Fourth Quarter Results
MT
Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2024
CI
Knight Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Knight Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
North American Morning Briefing : Investors -2-
DJ
Knight Therapeutics Announces Launch of Minjuvi in Brazil
MT
Knight Therapeutics Brief: Announcing Launch of Minjuvi in Brazil
MT
Knight Therapeutics Brief: Announcing Regulatory Submission Of Fostamatinib In Brazil
MT
Knight Therapeutics Inc. Announces Regulatory Submission of Fostamatinib in Brazil
CI
Knight Therapeutics Announces Launch of Bijuva in Canada
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GUD Stock
  4. KHTRF Stock
  5. News Knight Therapeutics Inc.
  6. Highlights